The safety and efficacy of sonidegib for the treatment of locally advanced basal cell carcinoma

Nicholas J. Collier, Faisal R. Ali, John T. Lear

    Research output: Contribution to journalArticlepeer-review

    116 Downloads (Pure)


    Introduction: Basal cell carcinomas (BCCs) are the commonest malignancy in the Western world. Locally advanced BCCs (laBCCs) represent tumours that have developed in difficult-to-treat facial sites, aggressively recurrent tumours, large neglected tumours and those in which current treatment options are excluded by clinical or patient-driven criteria. It is estimated laBCCs represent 1% of BCCs. Areas covered: Sonidegib is an oral hedgehog pathway inhibitor with a novel structure. It has recently been licensed for the treatment of laBCC. This article provides a comprehensive review of the literature regarding sonidegib, detailing the pharmacology of the compound, clinical trial data, competitor compounds and a future perspective. Expert commentary: Sonidegib is a novel smoothened (SMO) inhibitor with comparable efficacy to vismodegib, with patient response rates of 44% (sonidegib) and 43% (vismodegib). The adverse effect profile of these two treatments is similar with the main effects being considered to be class effects of SMO inhibitors.

    Original languageEnglish
    Pages (from-to)1011-1018
    Number of pages8
    JournalExpert Review of Anticancer Therapy
    Issue number10
    Publication statusPublished - 2 Oct 2016


    • Basal cell carcinoma
    • hedgehog pathway inhibitors
    • locally advanced basal cell carcinoma
    • small-molecule inhibitors
    • smoothened inhibitors
    • sonidegib


    Dive into the research topics of 'The safety and efficacy of sonidegib for the treatment of locally advanced basal cell carcinoma'. Together they form a unique fingerprint.

    Cite this